Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Cardiovascular Disease and Lipoprotein(a)

In brief

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Key facts

Study ID
NCT04023552
Run by
Novartis Pharmaceuticals
People needed
8323
Starts
2019-12-12
Expected to finish
2026-06-30
Last updated by the study team
2026-05-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.